Syantra, a Calgary, Canada-based precision biotechnology company, raised CAD$4.9M in Series A-1 funding.
The round was led by CG Wealth Management, with participation from existing investors.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Rob Lozuk, Syantra is a precision biotechnology company advancing a platform to change the way cancer is detected and treated. The Syantra DX™ Breast Cancer test, which is the first one developed on its biotechnology platform, measures a panel of gene expression biomarkers from whole blood and produces a test result with machine learning informed software, with 92% clinical accuracy in blinded clinical studies.
Syantra has an ISO 13485:2016-accredited quality management system and has received CLIA/COLA and CPSA lab accreditations for use of the test in the United States and Canada, respectively. Other regulatory approvals include CE-IVD and UKCA Marking for kit distribution outside North America.
The company also announced the addition of Dr. Rick Mangat to its Board of Directors. Dr. Mangat brings over 20 years of experience as a medical device executive. He co-founded NOVADAQ Technologies Inc. in 2000 and served as the company CEO until the company was acquired in September 2017.
FinSMEs
11/09/2024